The Claim
Phosphocyclocreatine accumulates in C6 rat glioma cells following exposure to cyclocreatine, as detected by intrinsic 31P-NMR spectroscopy, but does not accumulate in OC238 human ovarian carcinoma cells, suggesting divergent metabolic processing of cyclocreatine between these two cancer cell lines.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When scientists gave a substance called cyclocreatine to two types of cancer cells, one kind (from rat brain tumors) stored a modified version of it, but the other kind (from human ovarian tumors) didn't — meaning these cells handle the substance differently.
See the scientific wording
Phosphocyclocreatine accumulates in C6 rat glioma cells after cyclocreatine exposure, as detected by intrinsic 31P-NMR signal, but no such accumulation occurs in OC238 human ovarian carcinoma cells, indicating divergent metabolic processing of cyclocreatine between these two cancer cell lines.
What the research says
1 studyThe study shows that when treated with cyclocreatine, one type of cancer cell turns it into a different molecule (phosphocyclocreatine), but another type doesn’t — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.